Cancers · 2024 · 13 citations · 21 references
PharmacyPharmacokineticsPharmacologyCancer PharmacologyOncology PharmacotherapySolid Tumor PharmacotherapyDose Adjustment In OncologyDose SchedulingPharmacokinetics In Children With CancerPharmacokinetics Of Anticancer DrugsToxicity ManagementDose-limiting Toxicity AssessmentSerious Adverse EventsTherapeutic Dose RangeTreatment Cycle Scheduling
Background: Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify a maximum tolerated dose (MTD), pharmacokinetics (PK), a dosing schedule, and adverse events (AEs) in patients with advanced solid tumors. Patients and Methods: Patients received oral bimiralisib to determine the MTD of one continuous (once daily) and two intermittent schedules (A: Days 1, 2 weekly; B: Days 1, 4 weekly) until progression or unacceptable AEs occurred. Results: The MTD for the continuous schedule was 80 mg, with grade three fatigue as the dose-limiting toxicity (DLT). No MTD was reached with intermittent schedules, with only one DLT in schedule B. PK analysis suggested that 140 mg (schedule A) was within the biologically active dose range and was selected for further exploration. The most frequent treatment-emergent AEs were hyperglycemia (76.2%) in the continuous schedule, and nausea (56–62.5%) in schedules A and B. The most frequent treatment-emergent > grade three AE for all schedules combined was hyperglycemia (28.6%, continuous schedule; 12.0%, schedule A; 12.5%, schedule B). There was one partial response in a head and neck squamous cancer patient with a NOTCH1T1997M mutation. Conclusions: Bimiralisib demonstrated a manageable AE profile consistent with this compound class. Intermittent schedules had fewer > grade three AEs, while also maintaining favorable PK profiles. Intermittent schedule A is proposed for further development in biomarker-selected patient populations.
21
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga, Mario Campone, Martine Piccart et al. · New England Journal of Medicine · 2011 · 2.8K citations · Full text
Medicine, Oncology, Pharmacology +9
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman, Jeff P. Sharman, Steven Coutré et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell et al. · New England Journal of Medicine · 2023 · 704 citations · Full text
Medicine, Oncology, Pharmacology +16